熊猫体育-官网网址

About Genor
熊猫体育-官网网址about us

Founded in 2007, 熊猫体育-官网网址. (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's most prevalent cancer Types (breast, lung, and gastrointestinal cancer) and hematological malignancies.

?

Genor Biopharma strives to build an innovative, platform-oriented and integrated company with innovative drug R&D, preclinical research, clinical development, regulatory, and CMC development.

?

Successfully set up an early discovery platform with first in class (FIC)/differentiated T-cell Engager (T-cell Engager) bi-specific/multi-specific antibodies in immune-oncology / bispecific antibody-drug conjugates (BsADC). The focus is to conduct molecular research that have the potential to become global best-in-class (BIC) products and have the greatest potential to produce clinical and commercially viable drugs.

?

The industry-leading R&D center has extensive large molecule CMC (Chemistry, Manufacturing, and Controls) development experience. It is capable of developing comprehensive bioprocesses and formulations, and manufacturing preclinical and clinical materials with advanced analytical, quality control, and quality assurance systems for compliance.

?

?

Beijing office

Yuxi, Yunnan - Principally Phase 3 and commercial manufacturing

Zhangjiang, Shanghai - R&D center, QC/Analytical center, cGMP sample manufacturing

South San Francisco, US - Bi-specific platform

熊猫体育-官网网址open quote
熊猫体育-官网网址close quote
Our Vision

We aspire to become a biopharmaceutical company with global presence, serving patients and society.

熊猫体育-官网网址open quote
熊猫体育-官网网址close quote
Our Mission

Our mission is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialization of innovative therapeutics initially for patients in China and gradually for patients globally.

熊猫体育-官网网址Our History